6:52AM ET 5/18/2022 MT NewswiresProtagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...
10:00AM ET 5/05/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
2:54PM ET 4/26/2022 MT NewswiresProtagonist Therapeutics (PTGX) shares slumped 53% by Tuesday afternoon, a day after the biopharmaceutical company said a phase 2 study of its proposed...
1:50PM ET 4/26/2022 MT NewswiresProtagonist Therapeutics (PTGX) shares slumped 49% amid heavy trading after the company reported topline data from a phase 2 trial of PN-943 in ulcerative...